CCC
EW icon

Crescent Capital Consulting’s Edwards Lifesciences EW Stock Holding History

Crescent Capital Consulting’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$9K Hold
73
– – ﹤0.01% 397
2021
Q3 		$8K Hold
73
– – ﹤0.01% 438
2021
Q2 		$8K Buy
+73
New +$6.88K ﹤0.01% 385

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crescent Capital Consulting's EW Position: Q4 2021 in Review

Crescent Capital Consulting held its Edwards Lifesciences (EW) position steady in Q4 2021 at 73 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #397.

Crescent Capital Consulting first reported a position in EW in Q2 2021 and has held it in 3 quarters since. 1,320 funds tracked by Wall St. Rank hold EW as of Q4 2021.

  • Crescent Capital Consulting held 73 shares of Edwards Lifesciences worth $9K as of Q4 2021.
  • Crescent Capital Consulting left its Edwards Lifesciences share count unchanged in Q4 2021.
  • Edwards Lifesciences made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #397 holding.
  • Crescent Capital Consulting first reported a position in Edwards Lifesciences in Q2 2021 and has held it in 3 quarters since.
  • 1,320 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.